Plans are shifting. New plan of biosimilars, a cheaper but available is expected to more designs can steer patients to a still costly version of branded than double in the next two specialty pharmacy, focus on biologic medicines, have started years and triple in the three the site of care, seek support to increase in the U.S. years after that. The global cell from drug manufacturers to Approvals for cell and gene and gene therapy market is lower member out-of-pocket therapies continue to grow at an projected to grow from $6.58 costs, demand integrated care unprecedented pace. Currently, billion in 2021 to $8.57 billion in management from PBMs and there are more than 1,000 2022, up 30%, and reach $21.33 health plans, and mitigate claims therapies in the development billion in 2026, a compounded 1 risk via authorization programs, and approval pipeline worldwide. annual growth rate of 26%. stop loss coverage, or captives. The number of therapies Plans that cover the use and cost 2023 Benefits Trends: The evolving workplace 65